This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Sarepta Therapeutics (SRPT) and Surgery Partners (SGRY)

Tipranks - Tipranks - Thu May 14, 3:56AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arvinas Holding Company (ARVN), Sarepta Therapeutics (SRPT) and Surgery Partners (SGRY).

Claim 55% Off TipRanks

Arvinas Holding Company (ARVN)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on Arvinas Holding Company, with a price target of $20.00. The company’s shares closed last Tuesday at $9.57, close to its 52-week low of $7.53.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 26.4% and a 56.0% success rate. Darout covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, Protagonist Therapeutics, and Monopar Therapeutics Inc. ;'>

Arvinas Holding Company has an analyst consensus of Moderate Buy, with a price target consensus of $16.08, which is a 63.6% upside from current levels. In a report issued on May 1, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Sarepta Therapeutics (SRPT)

Barclays analyst Eliana Merle maintained a Hold rating on Sarepta Therapeutics today and set a price target of $20.00. The company’s shares closed last Tuesday at $19.13.

According to TipRanks.com, Merle is a 3-star analyst with an average return of 3.4% and a 41.6% success rate. Merle covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Ultragenyx Pharmaceutical, and Madrigal Pharmaceuticals. ;'>

Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $21.68, which is an 11.8% upside from current levels. In a report issued on May 5, TipRanks – xAI also upgraded the stock to Hold with a $22.50 price target.

Surgery Partners (SGRY)

Barclays analyst Andrew Mok CFA maintained a Hold rating on Surgery Partners today and set a price target of $14.00. The company’s shares closed last Tuesday at $13.97.

According to TipRanks.com, CFA ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.6% and a 50.5% success rate. CFA covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Alignment Healthcare. ;'>

Surgery Partners has an analyst consensus of Moderate Buy, with a price target consensus of $19.75, a 43.7% upside from current levels. In a report issued on May 6, KeyBanc also maintained a Hold rating on the stock.

Read More on ARVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).